Effectiveness of leuprolide acetate 3-month depot (11.25 mg) in the treatment of patients with central precocious puberty: experience of (2012)
- Authors:
- USP affiliated authors: XAVIER, ANA CLAUDIA LATRÔNICO - FM ; MENDONÇA, BERENICE BILHARINHO DE - FM
- Unidade: FM
- DOI: 10.1159/000343184
- Subjects: PUBERDADE PRECOSE; TESTOSTERONA (NÍVEL); NEUROENDORCRINOLOGIA; HORMÔNOS (USO TERAPÊUTICO); RESUMOS (EVENTOS)
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Hormone research in paediatrics
- ISSN: 0301-0163
- Volume/Número/Paginação/Ano: v.78, n. suppl. 1, Res. P2-d2-750, p. 232, 2012
- Conference titles: 51th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE)
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
BRITO, Vinicius Nahime et al. Effectiveness of leuprolide acetate 3-month depot (11.25 mg) in the treatment of patients with central precocious puberty: experience of. Hormone research in paediatrics. Basel: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1159/000343184. Acesso em: 21 maio 2024. , 2012 -
APA
Brito, V. N., Cukier, P., Lima, L. O., Silveira, L. F. G., Teles, M., Mendonça, B. B., et al. (2012). Effectiveness of leuprolide acetate 3-month depot (11.25 mg) in the treatment of patients with central precocious puberty: experience of. Hormone research in paediatrics. Basel: Faculdade de Medicina, Universidade de São Paulo. doi:10.1159/000343184 -
NLM
Brito VN, Cukier P, Lima LO, Silveira LFG, Teles M, Mendonça BB, Arnhold IJP, Latronico AC. Effectiveness of leuprolide acetate 3-month depot (11.25 mg) in the treatment of patients with central precocious puberty: experience of [Internet]. Hormone research in paediatrics. 2012 ;78( suppl. 1): 232.[citado 2024 maio 21 ] Available from: https://doi.org/10.1159/000343184 -
Vancouver
Brito VN, Cukier P, Lima LO, Silveira LFG, Teles M, Mendonça BB, Arnhold IJP, Latronico AC. Effectiveness of leuprolide acetate 3-month depot (11.25 mg) in the treatment of patients with central precocious puberty: experience of [Internet]. Hormone research in paediatrics. 2012 ;78( suppl. 1): 232.[citado 2024 maio 21 ] Available from: https://doi.org/10.1159/000343184 - Anthropometric, metabolic and reproductive outcome of patients with central precocious puberty due to hypothalamic hamartoma in adult life
- Puberdade precoce central
- Methylome profiling of healthy and central precocious puberty girls
- Clinical and molecular aspects of a pediatric metachronous adrenocortical tumor
- Mutational analysis of LIN28BGENE in children with idiopathic central precocious puberty
- Phenotype-genotype correlations in patients with inactivating gonadotropin hormone receptor mutations
- Molecular analysis of the neuropeptide Y1 receptor gene in human idiopathic gonadotropin-dependent precocious puberty and isolated hypogonadotropic hypogonadism
- Mutation in PTPN11 gene are a common cause of noonan syndrome (NS) but are not a selective IGF-1 receptor kinase inhibitor (NVP-AEW541) suppresses proliferation of the human adrenocortical cancer cell line NCI H295 due to apoptosis induction
- Fatores determinantes da estatura final normal em meninas com puberdade precoce dependente de gonadotrofinas tratadas com análogos de GnRII depot
- Análise dos valares de LH 2 horas após acetato de leuprolide depot na monitorização do tratamento da puberdade precoce dependente de gonadotrofinas
Informações sobre o DOI: 10.1159/000343184 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
